1. Home
  2. Analysis
  3. Gilenya
  4. Letairis

Gilenya and Letairis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gilenya (fingolimod) and Letairis (ambrisentan). Common drug interactions include asthenia among females and dysgeusia among males.

The phase IV clinical study analyzes what interactions people have when they take Gilenya and Letairis. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Gilenya?

Gilenya has active ingredients of fingolimod. It is often used in multiple sclerosis. eHealthMe is studying from 111,893 Gilenya users. Check the latest studies of Gilenya.

What is Letairis?

Letairis has active ingredients of ambrisentan. It is often used in pulmonary hypertension. eHealthMe is studying from 94,041 Letairis users. Check the latest studies of Letairis.

On Jul, 26, 2026

12 people who take Gilenya and Letairis together, and have interactions are studied.

Gilenya and Letairis drug interactions.

What are the common drug interactions of Gilenya and Letairis, by gender? *:

female:

  1. Asthenia (weakness)
  2. Mobility decreased (ability to move is reduced)
  3. Muscular weakness (muscle weakness)
  4. Neurogenic bladder (the normal function of the bladder is to store and empty urine in a coordinated, controlled fashion)
  5. Oedema (fluid collection in tissue)
  6. Oedema peripheral (superficial swelling)
  7. Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
  8. Urge incontinence (urinary incontinence)
  9. Pneumonia
  10. Blood pressure increased

male:

  1. Dysgeusia (disorder of the sense of taste)

What are the common drug interactions of Gilenya and Letairis, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Asthenia (weakness)
  2. Burning sensation
  3. Chest pain
  4. Constipation
  5. Headache (pain in head)
  6. Jugular vein distension (overloaded jugular vein)
  7. Lung transplant

50-59:

  1. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  2. Non-small cell lung cancer (type of epithelial lung cancer)

60+:

  1. Abdominal discomfort
  2. Acute sinusitis
  3. Pneumonia
  4. Alanine aminotransferase increased
  5. Aspartate aminotransferase increased
  6. Back pain
  7. Chest discomfort
  8. Dyspnoea (difficult or laboured respiration)
  9. Fatigue (feeling of tiredness)
  10. Heart rate decreased

What are the existing conditions these people have? *

  1. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 4 people, 33.33%
  2. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Gilenya and Letairis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Gilenya and Letairis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Gilenya:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Letairis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gilenya and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Letairis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on fingolimod and ambrisentan (the active ingredients of Gilenya and Letairis, respectively), and Gilenya and Letairis (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.